Back close

Pharmacotherapy for COVID-19

Publication Type : Journal Article

Publisher : Asian Journal of Pharmacy and Pharmacology

Source : Asian Journal of Pharmacy and Pharmacology, 2020; 6(5): 320-329

Url :

Campus : Kochi

School : School of Medicine

Department : Paediatrics

Year : 2020

Abstract : The past few months has witnessed mankind facing one of its toughest battles for survival till date. Severe acute respiratory syndrome caused by SARS CoV 2 has demonstrated its ability to bring humans to their knees at an unprecedented speed with no drugs or vaccine available till date. The objective of our review is to explore and compile various drugs tried for the Corona virus disease 19 across the world. We had vast literature search and shortlisted 164 articles. The drugs tried for the COVID -19 are given under category A, B and C. Category A need symptomatic treatment. Category B is given hydroxy chloroquine, azithromycin, and oseltamivir, Category C with hydroxy chloroquine and favipiravir. If favipiravir is contraindicated/not available, then hydroxychloroquine with either azithromycin or lopinavir/ritonavir for 14 days or 7 days after becoming asymptomatic is tried. In the Category C-moderate severity, Injection Remdesivir plus Injection Methyl prednisolone/Injection Dexamethasone is given. Patients with severe signs and symptoms (Respiratory Rate ≥ 30, SpO2 < 90 on room air) are suggested being initiated with Injection Remdesivir plus Injection Methyl prednisolone/Injection Dexamethasone. Convalescent plasma therapy to be initiated as per the respective state wise protocol in India. What we conclude is that, we advocates and describe the regimens used in everchanging guidelines for covid therapy in different part of the world. Special attention to symptomatic approach to treat the covid 19 disease in children has also been covered in this review article.

Cite this Research Publication : Princy Louis Palatty, Sathyajith G. Nair, Rosme David, Mamatha J., Vanditha S., Deepthi Mary George, Savithri P., P. G. Nayar, "Pharmacotherapy for COVID-19", Asian Journal of Pharmacy and Pharmacology, 2020; 6(5): 320-329

Admissions Apply Now